Literature DB >> 16080485

Neutropenic enterocolitis in an advanced epithelial ovarian cancer patient treated with paclitaxel/platinum-based chemotherapy: a case report and review of the literature.

Angiolo Gadducci1, Antonio Gargini, Elisabetta Palla, Antonio Fanucchi, Andrea Riccardo Genazzani.   

Abstract

BACKGROUND: Literature data show that neutropenic enterocolitis is a rare but severe complication that can occur in cancer patients treated with chemotherapy and especially with taxanes. CASE REPORT: A 60-year-old woman with stage Illc epithelial ovarian cancer developed neutropenic fever, abdominal pain, severe diarrhoea, nausea, vomiting and oral mucositis one week after the first postoperative cycle of paclitaxel (175 mg/m2 3-hour infusion) plus carboplatin-based chemotherapy. Abdominal X-ray showed diffuse dilatation of the ileal and colonic loops with air/fluid. The patient soon recovered after intensive supportive care. For the second cycle the dose of paclitaxel was reduced by 20%, but nine days later the patient again developed severe neutropenia with fever, abdominal colicky pain, diarrhoea and vomiting. The culture of blood samples collected on admission was found to be positive for Escherichia coli, whereas stools resulted negative for both enteric rods and Clostridium difficile toxin. The patient recovered with intensive supportive care, and chemotherapy was continued with single-agent carboplatin. DISCUSSION: The increasing use of paclitaxel in first-line as well as in the salvage treatment of epithelial ovarian cancer could increase the occurrence of neutropenic enterocolitis in patients with this malignancy. The importance of symptoms such as neutropenic fever, abdominal pain and tenderness and severe diarrhoea should be stressed in patients who receive taxane-based chemotherapy, and intensive supportive care management should be started immediately.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16080485

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

Review 1.  Necrotizing enterocolitis in neutropenia and chemotherapy: a clinical update and old lessons relearned.

Authors:  CelesteAnn T Bremer; Brian P Monahan
Journal:  Curr Gastroenterol Rep       Date:  2006-08

2.  Clostridium difficile infection in fever patients with gynecological malignancies.

Authors:  Shintaro Yanazume; Akio Tokudome; Mika Fukuda; Shinichi Togami; Masaki Kamio; Shunichiro Ota; Hiroaki Kobayashi
Journal:  Cancer Rep (Hoboken)       Date:  2019-07-22

3.  Neutropenic enterocolitis: current issues in diagnosis and management.

Authors:  Marta L Davila
Journal:  Curr Infect Dis Rep       Date:  2007-03       Impact factor: 3.725

4.  Concomitant typhlitis and Clostridium difficile colitis developed after first R-CHOP chemotherapy in a non-Hodgkin lymphoma patient.

Authors:  Parichart Junpaparp; Saranya Buppajarntham; Fernando Vargas Madueno; Gabor Varadi
Journal:  BMJ Case Rep       Date:  2013-04-17

Review 5.  Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Authors:  M Schmidt-Hieber; J Bierwirth; D Buchheidt; O A Cornely; M Hentrich; G Maschmeyer; E Schalk; J J Vehreschild; Maria J G T Vehreschild
Journal:  Ann Hematol       Date:  2017-11-24       Impact factor: 3.673

Review 6.  Rectal perforation following paclitaxel and carboplatin chemotherapy for advanced ovarian cancer: a case report and review of the literature.

Authors:  Sujen Jayakody; Danette Bianca Wright; Corrina Chiong; Mona Liu; Clare Bouffler; Toufic El-Khoury
Journal:  J Med Case Rep       Date:  2018-08-16

7.  Neutropenic Enterocolitis in the Treatment of Solid Tumors: A Case Report and Review of the Literature.

Authors:  Sara Cherri; Tiziana Prochilo; Luigina Rota; Stefano Mutti; Marco Garatti; Barbara Liserre; Alberto Zaniboni
Journal:  Case Rep Oncol       Date:  2020-04-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.